| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
|
N Engl J Med
|
2013
|
8.74
|
|
2
|
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
|
JAMA
|
2008
|
6.55
|
|
3
|
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
|
Ann Intern Med
|
2006
|
5.18
|
|
4
|
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
|
Stroke
|
2007
|
3.03
|
|
5
|
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.
|
Pharmacoepidemiol Drug Saf
|
2007
|
2.10
|
|
6
|
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
|
J Am Coll Cardiol
|
2011
|
1.73
|
|
7
|
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
|
Hypertension
|
2011
|
1.69
|
|
8
|
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.58
|
|
9
|
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
|
Thromb Haemost
|
2010
|
1.47
|
|
10
|
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.44
|
|
11
|
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
|
Thromb Haemost
|
2002
|
1.44
|
|
12
|
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
|
Hypertension
|
2012
|
1.14
|
|
13
|
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
|
Am J Cardiol
|
2006
|
1.12
|
|
14
|
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
|
Eur J Heart Fail
|
2013
|
1.04
|
|
15
|
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
|
Am Heart J
|
2008
|
1.02
|
|
16
|
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
|
Drug Saf
|
2009
|
0.96
|
|
17
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.95
|
|
18
|
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
|
J Am Coll Cardiol
|
2006
|
0.94
|
|
19
|
A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST).
|
Psychosom Med
|
2005
|
0.93
|
|
20
|
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
|
Am J Med
|
2012
|
0.91
|
|
21
|
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.
|
Pharmacotherapy
|
2006
|
0.89
|
|
22
|
Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
|
J Cardiovasc Pharmacol
|
2006
|
0.84
|
|
23
|
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
|
J Clin Hypertens (Greenwich)
|
2005
|
0.81
|
|
24
|
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
|
J Hypertens
|
2016
|
0.80
|
|
25
|
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
|
Blood Press Monit
|
2014
|
0.79
|
|
26
|
Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives.
|
Heart Fail Clin
|
2013
|
0.78
|
|
27
|
Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes.
|
J Am Coll Cardiol
|
2015
|
0.77
|
|
28
|
J curve in hypertension and coronary artery disease.
|
Am J Cardiol
|
2005
|
0.76
|
|
29
|
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
|
Thromb Haemost
|
2014
|
0.75
|
|
30
|
Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations.
|
Heart Fail Rev
|
2015
|
0.75
|
|
31
|
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
|
Am J Cardiovasc Drugs
|
2007
|
0.75
|